ALK and neuroblastoma: ALK inhibition with crizotinib reduced PD-L1 expression in silico and was validated in vitro, and this was not observed with mutant ALK tumours, suggesting neuroblastoma tumours with ALK mutations may be good candidates for PD-1 checkpoint inhibitors such as nivolumab [133].